Novel therapeutic strategies for treatment of visceral leishmaniasis

Related Experiment Video

Updated: May 8, 2026

Development of Leishmania Species Strains with Constitutive Expression of eGFP
10:03

Development of Leishmania Species Strains with Constitutive Expression of eGFP

Published on: April 21, 2023

Keerti Jain1, Narendra K Jain

  • 1Pharmaceutics Research Laboratory, Department of Pharmaceutical Sciences, Dr. H. S. Gour Central University, Sagar, MP 470003, India.

Drug Discovery Today
|August 27, 2013
PubMed

Insights

Visceral leishmaniasis treatment faces challenges from drug resistance and toxicity. This review explores novel therapeutic strategies to improve patient outcomes and guide future research in antileishmanial drug development.

Area of Science:

  • Parasitology
  • Infectious Diseases
  • Drug Discovery

Background:

  • Visceral leishmaniasis (VL) is a severe parasitic disease with limited treatment options.
  • Current antileishmanial drugs face challenges including toxicity, high cost, and increasing drug resistance.
  • Effective treatment of VL is crucial to prevent fatal complications.

Purpose of the Study:

  • To review and summarize novel therapeutic strategies for visceral leishmaniasis.
  • To provide a comprehensive overview of potential antileishmanial treatments.
  • To guide researchers in developing systematic approaches for VL treatment.

Main Methods:

  • Systematic literature review of novel therapeutic strategies for visceral leishmaniasis.
  • Analysis of current challenges in VL chemotherapy.
  • Exploration of emerging treatment modalities and drug targets.

Main Results:

  • Identified several promising novel therapeutic avenues for VL.
  • Highlighted the limitations of existing antileishmanial chemotherapeutic agents.
  • Discussed the importance of good tolerability and efficacy in new treatments.

Conclusions:

  • Novel therapeutic strategies are essential to overcome the limitations of current VL treatments.
  • Further research is needed to develop effective and well-tolerated antileishmanial agents.
  • This review provides a framework for advancing VL therapeutic research.

More Related Videos

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice06:57

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

Published on: February 20, 2020

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host09:53

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host

Published on: July 27, 2010

Related Concept Videos

Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...